Patents
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
09/2006
09/21/2006US20060211645 Modulation of neurodegenerative diseases
09/21/2006US20060211643 Polycations capable of forming complexes with nucleic acids
09/21/2006US20060211641 Modulation of immunostimulatory properties of oligonucleotide-based compounds by utilizing modified immunostimulatory dinucleotides
09/21/2006US20060211639 Immunostimulatory nucleic acids and cancer medicament combination therapy for the treatment of cancer
09/21/2006US20060211638 Exon 1 ss of pdgf alpha gene and utilization thereof
09/21/2006US20060211637 Methods of down regulating target gene expression in vivo by introduction of interfering rna
09/21/2006US20060211636 Macrolide Antibiotics
09/21/2006US20060211635 total pomegranate tannins (TPT) including punicalagin; nutraceutical for cardiovascular health
09/21/2006US20060211634 Antibiotic resistance
09/21/2006US20060211633 D-mannose contraceptives
09/21/2006US20060211632 PXR agonists for cardiovascular disease
09/21/2006US20060211631 Transfusion preparation for peripheral intravenous administration and method of stabilizing vitamin b1
09/21/2006US20060211628 Treatment of multiple sclerosis with brain targeted anti oxidant compounds
09/21/2006US20060211624 Methods and compositions for the treatment of parkinson's disease and other alpha-synucleinopathies
09/21/2006US20060211617 Methods, compositions and articles of manufacture for contributing to the treatment of solid tumors
09/21/2006US20060211613 Administering parathyroid hormone and bone resorption inhibitor; bone disorders
09/21/2006US20060211611 Therapies and compositions for controlling the stress mechanism and for stabilizing hemostasis in an organism
09/21/2006US20060211602 Use of alanyl aminopeptidase inhibitors and pharmaceutical compositions containing said inhibitors
09/21/2006US20060211599 Reversibly heat-gelable aqueous composition
09/21/2006US20060211114 Modulation of hedgehog-mediated signaling pathway
09/21/2006US20060211058 Diagnosis and treatment of malignant neoplasms
09/21/2006US20060211042 Methods of identifying modulators of cellular glycosylation using gtrap3-18
09/21/2006US20060211025 Molecular signatures of commonly fatal carcinomas
09/21/2006US20060211013 Method for sorting antifungal molecules acting on the glucanosyltransferase activity
09/21/2006US20060210974 Compositions and methods for preventing, treating and diagnosing diabetes
09/21/2006US20060210660 Process for preparing an extract from ivy leaves
09/21/2006US20060210659 Anti-obesity agent
09/21/2006US20060210657 Compositions and methods for prostate and kidney health and disorders, an herbal preparation
09/21/2006US20060210656 Synergistic Effects of Nuclear Transcription Factor NF-kB Inhibitors and Anti-Neoplastic Agents
09/21/2006US20060210653 Compositions and methods for increasing metabolism, thermogenesis and/or muscular definition
09/21/2006US20060210651 Methods and compositions involving aldose reductase
09/21/2006US20060210650 Supplemental dietary composition for promoting weight loss
09/21/2006US20060210648 Method for treating an inflammation or lesion caused by a virus
09/21/2006US20060210647 Copper-dependent non-traditional pro-inflammatory cytokine export and methods, compositions and kits relating thereto
09/21/2006US20060210646 Accelerator for mineral absorption and use thereof
09/21/2006US20060210645 Pharmaceutically acceptable carrier for ophthalmic compositions
09/21/2006US20060210640 Process for producing nanoparticles by spray drying
09/21/2006US20060210639 Nanoparticulate bisphosphonate compositions
09/21/2006US20060210638 Injectable compositions of nanoparticulate immunosuppressive compounds
09/21/2006US20060210637 Stable tablet dosage forms of proton pump inhibitors
09/21/2006US20060210632 Sublingual coated tablet of fentanyl
09/21/2006US20060210630 Controlled release compositions of gamma-hydroxybutyrate
09/21/2006US20060210628 Use of epinine for enhancing physical performance
09/21/2006US20060210625 Sustained release of positively charged pharmacologically active molecules from a matrix containing polymers with polarized oxygen atoms
09/21/2006US20060210624 Combination product comprising an antagonist or inverse agonist of histamine receptor h<sb>3 </sb>and an antipsychotic and antidepressant agent, and use thereof for the preparation of a medicament that prevents the adverse effects of psychotropic drugs
09/21/2006US20060210622 Surface modified particulate compositions of biologically active substances
09/21/2006US20060210621 consisting of partially hydrolyzed fucoidan, plum concentrate, grape concentrate, black currant concentrate, blueberry concentrate, raspberry concentrate, black pepper extract, Sichuan pepper extract, minerals, flavoring agent, and sweetener
09/21/2006US20060210620 Co-precipitated amorphous losartan and dosage forms comprising the same
09/21/2006US20060210619 Limposomes containing asiaticoside and the uses thereof
09/21/2006US20060210618 Polyglycrine based phospholipid containing amide groups; surfactant, solubilizer, dispersant for cosmetics, lipid membrane for drug delivery systems
09/21/2006US20060210617 Selected solvent is one that can substantially or fully solvate or dissolve the adhesive while keeping the fentanyl suspended in the solvated adhesive; provides non-invasive sustained analgesia for periods ranging from 24 hours to 168 hours
09/21/2006US20060210615 Dermal or transdermal therapeutic system comprising an ormocer with barrier effect on a cover foil
09/21/2006US20060210614 Method of treatment of a metabolic disease using intranasal administration of exendin peptide
09/21/2006US20060210613 Therapeutic wound care product
09/21/2006US20060210609 Fucoidan compositions and methods for dietary and nutritional supplements
09/21/2006US20060210607 plant extracts from soybean, extracted in the presence of cyclodextrin ; enzymatically-modified isoflavones; easy adsorbed by the body, kept therein at a high concentration for a long time; increase the bone density and prevent osteoporosis; beverages, cosmetics, pharmaceuticals, or feeds;
09/21/2006US20060210606 Food for improving clinical conditions capable of lowering the concentration of low-molecular weight nitrogen-containing compounds in blood
09/21/2006US20060210593 Methods of making and methods of using antiseptic disinfectant, cosmetic and toiletries, medicine or food containing the same
09/21/2006US20060210592 Use of rifaximin for the prevention of aspiration pneumonia and/or sepsis
09/21/2006US20060210571 Engineering antibodies that bind irreversibly
09/21/2006US20060210568 Methods and compositions for cancer treatment
09/21/2006US20060210565 Antagonists of HMG1 for treating inflammatory conditions
09/21/2006US20060210561 Dosages for treatment with anti-EGFR antibodies
09/21/2006US20060210557 Stabilized liquid polypeptide formulations
09/21/2006US20060210555 Compositions comprising immunoreactive reagents and saponins, and methods of use thereof
09/21/2006US20060210553 Topical use of tyrosine kinase inhibitors of microbial origin to prevent and treat skin disorders characterised by excesssive cell proliferation
09/21/2006US20060210552 Compositions and methods for systemic inhibition of cartilage degradation
09/21/2006US20060210551 Use of a mast cell activation or degranulation blocking agent in the manufacture of a medicament for the treatment of a patient subjected to thrombolyses
09/21/2006US20060210548 Method for reducing obstructive hydrocephalus
09/21/2006US20060210546 Athlete dietary supplement
09/21/2006US20060210533 Compounds and compositions for delivering active agents
09/21/2006US20060210532 Means and methods for the recruitment and identification of stem cells
09/21/2006US20060210530 Polymer coating of cells
09/21/2006US20060210529 Method of attenuating neurogenic bruise formation
09/21/2006US20060210528 Therapy for tropical diseases
09/21/2006US20060210527 Cyclodextrin-based polymers for therapeutics delivery
09/21/2006US20060210526 polyoxyethylene glycol-protein conjugate linked via linking group
09/21/2006US20060210525 Dispersions
09/21/2006US20060210516 Article with skin protecting and moisturizing compound
09/21/2006US20060210515 Hair growth formula
09/21/2006US20060210514 Skin protection and moisturizing compositions and method of making the same
09/21/2006US20060210504 Compositions and methods for inhibiting eccrine perspiration in humans
09/21/2006US20060210492 Use of rifaximin for treatment and prevention of periodontal conditions
09/21/2006US20060210485 Pharmaceutical formulations
09/21/2006US20060210484 Transmucosal absorption through oral mucosa to systemic circulatory system; bioavailability, rapid onset; active ingredient, solvent and low molecular weight hydrocarbon propellant
09/21/2006US20060210483 Non-systemic antibiotic formulations and related method of use and treatment of upper respiratory infections
09/21/2006US20060210482 Chemical composition and method for cold and sinus relief
09/21/2006US20060210480 Treatment of reduction of dysphagia
09/21/2006US20060210479 Targeting chelants and chelates
09/21/2006US20060210477 Therapeutic agent for cancer
09/21/2006US20060210475 Humanized L243 antibodies
09/21/2006DE4404086B4 Pharmazeutische und/oder kosmetische Zusammensetzung Pharmaceutical and / or cosmetic composition
09/21/2006DE4404085B4 Pharmazeutische und/oder kosmetische Zusammensetzung Pharmaceutical and / or cosmetic composition
09/21/2006DE202006009610U1 Chitin, beta 1,3/1,6 D glucan and melanin bio spray, useful for fighting against foot fungus and simultaneous recovery of affected areas, comprises chitin, beta 1,3/1,6 D glucan and melanin complex, where the bio spray is a dry spray
09/21/2006DE19681478B4 R-(-)-(E)-[4-(2,4-Dichlorphenyl)-1,3-dithiolan-2-yliden]-1-imidazolylacetonitril,Verfahren zu seiner Herstellung und seine Verwendung R - (-) - (E) - [4- (2,4-dichlorophenyl) -1,3-dithiolan-2-ylidene] -1-imidazolylacetonitril, process for its preparation and its use
09/21/2006DE102006011111A1 Formulation for analgesic ear drops contains polyhydric alcohol, especially butan-1,3-diol or glycerol, dimethyl sulfoxide and optionally acid or buffer system and dexpanthenol
09/21/2006DE102005012875A1 Verwendung von Amino substituierten 8-N-Benzimidazolen Use of amino-substituted 8-N-benzimidazoles
09/21/2006DE102005012874A1 Amid substituierte 8-N-Benzimidazole, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel Amide substituted 8-N-benzimidazoles, process for their preparation and their use as medicaments
09/21/2006DE102005012831A1 Herstellung eines Arzneimittels zur Senkung des Risikofaktors der Artherosklerose und/oder Erhöhung der Insulinsensitivität Manufacture of a medicament for reducing the risk factor of atherosclerosis and / or increasing insulin sensitivity
09/21/2006DE102005012681A1 New 1,5-dihydro-pyrrol-2-one compounds are HDM2 inhibitors, useful for treating e.g. stroke, heart infarct, ischemia, multiple sclerosis, Alzheimer's disease, degenerative disease, viral infection and cancer